Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital health platforms. The deal will take effect later this month. As part of the arrangement, Hims & Hers will stop advertising compounded GLP‑1 products and will give existing patients the option to transition to branded, FDA‑approved medicines when clinically appropriate. This news come...